发明名称 Method of treating connective tissue defect using chondrocytes selected for phenotypic stability
摘要 An in vivo assay to measure anchorage-independent growth and phenotypic stability of a certain cell population comprising subcutaneous or intramuscular injection in a mammal of a cell suspension of articular chondrocytes in an iso-osmotic liquid, the same suspension comprising articular chondrocytes in an amount equivalent to at least 1×106 chondrocytes as applied to immune-deficient mice. The outcome is linked to molecular markers. The present invention further relates to DNA chips and diagnostic tools comprising the latter to predict the outcome of ACT. Antibodies raised against positive and negative markers of chondrocyte stability can also be used for quality control on the chondrocytes. Therapeutical composition comprising stable chondrocytes are very useful for tissue repair.
申请公布号 US9089598(B2) 申请公布日期 2015.07.28
申请号 US200812323185 申请日期 2008.11.25
申请人 TIGENIX N.V. 发明人 Luyten Frank;Bari Cosimo De;Dell'Accio Francesco
分类号 C12N5/00;A61K49/00 主分类号 C12N5/00
代理机构 Clark & Elbing LLP 代理人 Clark & Elbing LLP
主权项 1. A method of treating a connective tissue defect in a patient comprising the step of transplanting chondrocytes to a connective tissue site in a patient, using passaged chondrocytes that have been prepared using the method steps of : a) providing articular cartilage from said patient b) isolating chondrocytes from said articular cartilage by enzymatic digestion c) expanding said isolated chondrocytes by serial passaging, d1) detecting in said passaged chondrocytes the expression of bone morphogenic protein-2(BMP-2), fibroblast growth factor receptor 3 (FGFR-3), or Collagen type II, or d2) detecting in said passaged chondrocytes the expression of activin-like kinase-1 (ALK-1) or Collagen type X e) selecting a cell population of passaged chondrocytes wherein a cell population that has either (1) expression of BMP-2, FGR-3 or collagen type II or has (2) no expression of Collagen Type X or no expression of ALK-1 is selected, f) transplanting said cell population to a connective tissue site in said patient.
地址 Leuven BE